Phase II Study of the Addition of Azacitidine (IND87574, NSC102816) to Reduced-Intensity Conditioning Allogeneic Transplantation for Myelodysplasia (MDS) and Older Patients With AML.

Trial Profile

Phase II Study of the Addition of Azacitidine (IND87574, NSC102816) to Reduced-Intensity Conditioning Allogeneic Transplantation for Myelodysplasia (MDS) and Older Patients With AML.

Active, no longer recruiting
Phase of Trial: Phase II

Latest Information Update: 13 Jul 2017

At a glance

  • Drugs Azacitidine (Primary) ; Azacitidine (Primary) ; Antithymocyte globulin; Busulfan; Fludarabine; Methotrexate; Tacrolimus; Tacrolimus
  • Indications Acute myeloid leukaemia; Graft-versus-host disease; Myelodysplastic syndromes
  • Focus Therapeutic Use
  • Most Recent Events

    • 06 Sep 2012 Planned end date changed from Mar 2013 to 1 Jul 2017 as reported by ClinicalTrials.gov.
    • 06 Sep 2012 Planned end date changed from 1 Mar 2013 to 1 Jul 2013 as reported by ClinicalTrials.gov.
    • 13 Jan 2011 Additional trial centres identified as reported by ClinicalTrials.gov.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top